dibenzthione: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 67686 |
CHEMBL ID | 151803 |
CHEBI ID | 31477 |
SCHEMBL ID | 155101 |
MeSH ID | M0060244 |
Synonym |
---|
CCG-199943 |
carbothialdine |
dibenzthion |
dibenzothione |
carbothialdin d47 |
350-12-9 |
sulbentin |
2h-1,5-thiadiazine-2-thione, tetrahydro-3,5-bis(phenylmethyl)- |
mecal |
noticin |
afungin |
2h-1,5-thiadiazine-2-thione, 3,5-dibenzyltetrahydro- |
fungiplex |
d 47 |
mls003106337 , |
sulbentine , |
nsc150555 |
refungine |
nsc-150555 |
dibenzthione |
NCGC00160606-01 |
sulbentine (inn) |
dibenzthion (jan) |
D01335 |
nsc 150555 |
3,5-dibenzyl-2-thion-tetrahydro-1,3,5-thiadiazin [german] |
einecs 206-497-2 |
brn 0544719 |
3,5-dibenzyltetrahydro-2h-1,3,5-thiadiazine-2-thione |
tetrahydro-3,5-dibenzyl-2h-1,3,5-thiadiazine-2-thione |
sulbentina [inn-spanish] |
2h-1,3,5-thiadiazine-2-thione, tetrahydro-3,5-bis(phenylmethyl)- |
2h-1,3,5-thiadiazine-2-thione, tetrahydro-3,5-dibenzyl- |
3,5-dibenzylperhydro-1,3,5-thiadiazine-2-thione |
2h-1,3,5-thiadiazine-2-thione, 3,5-dibenzyltetrahydro- |
sulbentinum [inn-latin] |
sulbentine [inn] |
MAYBRIDGE4_003705 |
MLS001249466 |
smr000040461 |
HMS1531I09 |
bdbm50084132 |
3,5-dibenzyl-[1,3,5]thiadiazinane-2-thione |
MLS001249428 |
CHEMBL151803 , |
chebi:31477 , |
dibenzathione |
BRD-K72384124-001-01-5 |
3,5-dibenzyl-1,3,5-thiadiazinane-2-thione |
AKOS002098909 |
3,5-dibenzyl-2-thion-tetrahydro-1,3,5-thiadiazin |
unii-d0nr12wk9j |
d0nr12wk9j , |
dtxcid5026257 |
tox21_111932 |
dtxsid7046257 , |
cas-350-12-9 |
HMS2875M06 |
sulbentina |
sulbentinum |
tetrahydro-3,5-bis(phenylmethyl)-2h-1,3,5-thiadiazine-2-thione |
sulbentine [mart.] |
sulbentine [who-dd] |
sulbentine [mi] |
dibenzthion [jan] |
MLS006011652 |
SCHEMBL155101 |
CS-4738 |
cyto8c8 |
HY-B1133 |
DB13671 |
Q2364327 |
BRD-K72384124-001-07-2 |
F85243 |
MS-24623 |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Class | Description |
---|---|
aromatic amine | An amino compound in which the amino group is linked directly to an aromatic system. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 100.0000 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Nrf2 | Homo sapiens (human) | Potency | 15.8489 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 10.0000 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
USP1 protein, partial | Homo sapiens (human) | Potency | 15.8489 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
TDP1 protein | Homo sapiens (human) | Potency | 23.3022 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
AR protein | Homo sapiens (human) | Potency | 33.4915 | 0.0002 | 21.2231 | 8,912.5098 | AID743042 |
Smad3 | Homo sapiens (human) | Potency | 15.8489 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 19.9526 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 15.8489 | 0.0123 | 7.9835 | 43.2770 | AID1346984 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 11.2202 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 2.6832 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 14.1254 | 0.0054 | 28.0263 | 1,258.9301 | AID1346985 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 23.5175 | 0.0002 | 29.3054 | 16,493.5996 | AID743079; AID743080; AID743091 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 12.0652 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 20.2677 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 15.8489 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 21.7356 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 31.6228 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 15.2573 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 20.5029 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 14.3818 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 5.6234 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.0316 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 0.4467 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 0.5956 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 15.8489 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Delta-type opioid receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 28.6000 | 0.0003 | 0.3887 | 7.0000 | AID149518 |
Mu-type opioid receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 27.9000 | 0.0001 | 0.8874 | 10.0000 | AID151438 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID151438 | In vitro inhibition of [3H]DAMGO (Tyr-D-Ala-Gly-(Me)-Phe-Gly-ol) binding to Opioid receptor mu 1 using rat brain membranes | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand. |
AID149518 | In vitro inhibition of [3H]- [p-Cl-Phe4]DPDPE binding to Opioid receptor delta 1 using rat brain membranes. | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand. |
AID233589 | Ratio of IC50 of mu to delta receptors | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (8.33) | 18.7374 |
1990's | 1 (8.33) | 18.2507 |
2000's | 1 (8.33) | 29.6817 |
2010's | 7 (58.33) | 24.3611 |
2020's | 2 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |